Tsukuba, Japan

Hiroyuki Higashiyama


 


Average Co-Inventor Count = 4.5

ph-index = 1

Forward Citations = 1(Granted Patents)


Location History:

  • Tsukuba, JP (2015 - 2017)
  • Kamakura, JP (2023)

Company Filing History:


Years Active: 2015-2023

Loading Chart...
Loading Chart...
Loading Chart...
3 patents (USPTO):Explore Patents

Title: Hiroyuki Higashiyama: Innovator in Epilepsy and Pain Treatment

Introduction

Hiroyuki Higashiyama is a notable inventor based in Tsukuba, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in the development of treatments for epilepsy and pain management. With a total of 3 patents to his name, Higashiyama continues to push the boundaries of medical innovation.

Latest Patents

Higashiyama's latest patents include a groundbreaking epilepsy treatment agent. This invention combines N-[(1S)-2,2,5,7-tetrafluoro-2,3-dihydro-1H-inden-1-yl]sulfamide with an AMPA-type glutamate receptor antagonist, showcasing potential as a therapeutic agent for epilepsy. Additionally, he has developed a therapeutic and preventive agent comprising 1-indansulfamide derivatives for pain management. This method involves administering various 1-indansulfamide compounds, including N-[(1S)-2,2,5,7-tetrafluoro-2,3-dihydro-1H-inden-1-yl]sulfamide, to effectively treat pain.

Career Highlights

Higashiyama is currently associated with Eisai R&D Management Co., Ltd., where he continues to innovate in the pharmaceutical sector. His work has garnered attention for its potential impact on improving the quality of life for individuals suffering from chronic conditions.

Collaborations

Higashiyama collaborates with esteemed colleagues such as Yuji Kazuta and Keisuke Hashimoto. Their combined expertise contributes to the advancement of research and development in their field.

Conclusion

Hiroyuki Higashiyama stands out as a prominent inventor in the pharmaceutical industry, with a focus on epilepsy and pain treatment. His innovative patents and collaborations reflect his commitment to enhancing medical therapies.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…